Single genetic mutations can account for melanocytic naevi

British Journal of Dermatology

Volumn 152, Issue 5, 2005, Pages 896-902

  Blewitt, R W ^a  

^a ROYAL LANCASTER INFIRMARY   (United Kingdom)

Author keywords

Genetic mutations; Hypothesis; Melanocytic naevi; Pathogenesis

Indexed keywords

ADULT; ARTICLE; CELL POPULATION; CLINICAL FEATURE; COMPARATIVE STUDY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MELANOCYTE; MELANOCYTIC NEVUS; MITOSIS; MODEL; NEUROFIBROMA; NEUROFIBROMATOSIS; ONSET AGE; PRIORITY JOURNAL; STEM CELL;

CELL DIVISION; HUMANS; MELANOCYTES; MODELS, GENETIC; MUTATION; NEVUS, PIGMENTED; SKIN NEOPLASMS; TUMOR STEM CELLS;

EID: 18944373020     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06571.x     Document Type: Article

References (48)

1. Mackie RM, English J, Aitchison TC et al. The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol 1985; 113:167-74.
2. Mehregan AH, Hashimoto K, Mehregan DA, Mehregan DR. Malformation and neoplasia. In: Pinkus's Guide to Dermatopathology, 6th edn. Norwalk, CT: Appleton & Lange, 1995; 462-7.
3. Happle R. What is a nevus? A proposed definition of a common medical term. Dermatol 1995; 191:1-5.
4. Walton RG, Jacobs AH, Cox AJ. Pigmented lesions in newborn infants. Br J Dermatol 1976; 95:389-96.
5. Lutd HZ, Stobbe GD. The natural history of the pigmented nevus: factors of age and anatomic location. Am J Pathol 1949; 25:1117-45.
6. Shelley WB. Photographic evidence of the spontaneous involution and disappearance of pigmented nevi; case report. Arch Dermatol 1960; 81:208-9.
7. Harper JI. Genetics and genodermatoses. In: Textbook of Dermatology (Champion RH, Burton JL, Burns DA, Breathnach SM, eds), 6th edn, Vol. 1. Oxford: Blackwell Science, 1998; 357-436.
8. Serra E, Puig S, Otero D et al. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet 1997; 61:512-19.
9. Osborn MJ, Upadhyaya M. Evaluation of the protein truncation test and mutation detection in the NF1 gene: mutational analysis of 15 known and 4-0 unknown mutations. Hum Genet 1999; 105:327-32.
10. Weiss B, Bollag G, Shannon K. Hyperactive ras as a therapeutic target in neurofibromatosis type 1. Am J Med Gen 1999; 89:14-22.
11. Sawada S, Florell S, Purandare SM et al. Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat Genet 1996; 14:110-12.
12. Rosdahl I, Rorsman H. An estimate of the melanocyte mass in humans. J Invest Dermatol 1983; 81:278-81.
13. Simpson AJG. The natural somatic mutation frequency and human carcinogenesis. Adv Cancer Res 1997; 71:209-40.
14. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991; 51:3075-9.
15. Boyer JC, Farber RA. Mutation rate of a microsatellite sequence in normal human fibroblasts. Cancer Res 1998; 58:3946-9.
16. Morris JA. Spontaneous mutation rate in retinoblastoma. J Clin Pathol 1990; 43:496-8.
17. Orr-Weaver TL, Weinberg RA. A checkpoint on the way to cancer. Nature 1998; 392:223-4.
18. Nordlund JL. Introduction to the biology of the pigment system. In: Dermatology (Moschella SL, Hurley HL, eds). 3rd edn. Philadelphia: W.B.Saunders, 1991; 1421-41.
19. Jakubovic HR, Ackerman AB. Structure and function of skin: development, morphology and physiology. In: Dermatology (Moschella SL, Hurley HL, eds), 3rd edn. Philadelphia: W.B.Saunders, 1992; 3-87.
20. Joint Formulary Committee. Prescribing for children. In: British National Formulary, Vol 42. Oxon: Pharmaceutical Press, 2001; 11.
21. Sagebiel RW, Odland GF. Ultrastructural identification of melanocytes in early human embryos. In: Pigmentation: its Genesis and Biologic Control (Riley V, ed.). New York: Appleton-Century-Crofts, 1972; 43-50.
22. Nishimura EK, Jordan SA, Oshima H et al. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 2002; 416:854-60.
23. Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990; 110:1001-19.
24. Rampen FH, de Wit PE. Racial differences in mole proneness. Acta Derm Venereol 1989; 69:234-6.
25. Green A, Siskind V, Hansen ME et al. Melanocytic nevi in schoolchildren in Queensland. J Am Acad Dermatol 1989; 20:1054-60.
26. Kelly JW, Rivers JK, MacLennan R et al. Sunlight: a major factor associated with the development of melanocytic nevi in Australian schoolchildren. J Am Acad Dermatol 1994; 30:40-8.
27. Baird EA, McHenry PM, MacKie RM. Effect of maintenance chemotherapy in childhood on numbers of melanocytic naevi. BMJ 1992; 305:799-801.
28. Hughes BR, Cunliffe WJ, Bailey CC. Excess benign melanocytic naevi after chemotherapy for malignancy in childhood. BMJ 1989; 299:88-91.
29. Fitzpatrick TB, Szabo G, Mitchell RE. Age changes in the human melanocyte system. In: Aging. Proceedings of the Symposium Held at the University of Oregon Medical School 1964 (Advances in Biology of Skin, Vol. 6. (Montagna W, ed.). Oxford: Pergamon, 1965; 35-56.
30. Gilchrest BA, Blog FB, Szabo G. Effects of aging and chronic sun exposure on melanocytes in human skin. J Invest Dermatol 1979; 73:141-3.
31. Mark GJ, Mihm MC, Liteplo MG et al. Congenital melanocytic nevi of the small and garment type. Clinical, histologic, and ultrastructural studies. Hum Pathol 1973; 4:395-418.
32. Healy E, Belgaid CE, Taketa M et al. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res 1996; 56:589-93.
33. Maitra A, Gazdar AF, Moore TO, Moore AY. Loss of heterozygosity analysis of cutaneous melanoma and benign melanocytic nevi: laser capture microdissection demonstrates clonal genetic changes in acquired melanocytic nevi. Hum Pathol 2002; 33:191-7.
34. INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet 1999; 36:610-14.
35. McKee PH. Pathology of the Skin, 2nd edn. London: Mosby-Wolfe, 1996; 1648-9.
36. Mackie RM. Melanocytic naevi and malignant melanoma. In: Textbook of Dermatology (Champion RH, Burton JL, Burns DA, Breathnach SM, eds) 6th edn, Vol. 2. Oxford: Blackwell Science, 1998; 1717-52.
37. Wagner SN, Ockenfels HM, Wagner C et al. Ras gene mutations: a rare event in nonmetastatic primary malignant melanoma. J Invest Dermatol 1995; 104:868-71.
38. Shahbazi M, Pravica V, Nasreen N et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002; 359:397-401.
39. Walker GJ, Hayward NK. p16INK4A and p14ARF tumour suppressors in melanoma: lessons from the mouse. Lancet 2002; 359:7-8.
40. Bartkova J, Lukas J, Guldberg P et al. The p16-cyclin D/Cdk4-pRB pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56:5475-83.
41. Lynch HT, Frichot BC, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978; 15:352-6.
42. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 2000; 42:705-22.
43. Swerdlow AJ, English J, MacKie RM et al. Benign melanocytic naevi as a risk factor for malignant melanoma. BMJ 1986; 292:1555-9.
44. Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 2001; 12:69-82.
45. Johnson L, Mercer K, Greenbaum D et al. Somatic activation of the K-ras oncogene causes early onset King cancer in mice. Nature 2001; 410:1111-16.
46. 1/S transition. In: Cancer Surveys, Vol. 29 (Kastan MB, ed.). New York: Cold Spring Harbour Laboratory Press, 1997; 7-23.
47. Feldkamp MM, Angelov L, Guha A. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway. Surg Neurol 1999; 51:211-18.
48. Peeper DS, Upton TM, Ladha MH et al. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 1997; 386:177-81.